Niche NICU focus Target smaller biotech and niche clinical programs aiming at neonatal care, with a clear opportunity to position pagibaximab as a preventive monoclonal antibody for staphylococcal sepsis in VLBW infants.

One product in focus Leverage the lead candidate pagibaximab alongside two additional candidates to pursue partnerships or licensing deals for multiple anti-staphylococcal therapies, broadening potential revenue streams in hospital settings.

Clinical unmet need Emphasize high-urgency, high-need NICU indications for infection prevention and treatment, aligning outreach with医院 procurement and pediatric infectious disease teams seeking innovative solutions.

Financial modesty With reported revenue in the mid tens of millions and a small team, pursue early-stage partnerships, grant-funded programs, and co-development pilots to accelerate market entry while managing dilution risk.

Tech and footprint Highlight a lean tech stack and modern web presence to support digital outreach, while offering scalable collaboration with larger pharma or CRO networks for rapid development and regulatory support.